Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
7u66grNK4YPFgCAt
Listen
